Kallikrein
From Proteopedia
(Difference between revisions)
| Line 9: | Line 9: | ||
*'''KLK5''' and '''KLK7''' regulate cell shedding.<br /> | *'''KLK5''' and '''KLK7''' regulate cell shedding.<br /> | ||
*'''KLK6''' regulates immune cells survival.<br /> | *'''KLK6''' regulates immune cells survival.<br /> | ||
| + | *'''KLK8''' is involved inproteolytic cascade in the skin.<br /> | ||
*'''plasma KLK''' cleaves Arg and Lys in kininogen to release bradykinin.<br /> | *'''plasma KLK''' cleaves Arg and Lys in kininogen to release bradykinin.<br /> | ||
*'''Tissue KLK''' is expressed throughout the body.<br /> | *'''Tissue KLK''' is expressed throughout the body.<br /> | ||
== Disease == | == Disease == | ||
| - | Activation of the plasma KLK pathway may contribute to diabetic macular edema<ref>PMID:20535647</ref>. KLK6 is implicated in carcinogenesis, Alzheimer and Parkinson diseases<ref>PMID:16800739</ref>.<br />. | + | Activation of the plasma KLK pathway may contribute to diabetic macular edema<ref>PMID:20535647</ref>. KLK6 is implicated in carcinogenesis, Alzheimer and Parkinson diseases<ref>PMID:16800739</ref>. KLK8 processes papilloma virus fascilitating their entry to host cells<ref>PMID:25926655</ref>.<br />. |
== Structural highlights == | == Structural highlights == | ||
| Line 54: | Line 55: | ||
**[[1l2e]], [[1lo6]] – hKLK + inhibitor <br /> | **[[1l2e]], [[1lo6]] – hKLK + inhibitor <br /> | ||
**[[3vfe]], [[4d8n]] – hKLK (mutant) + inhibitor <br /> | **[[3vfe]], [[4d8n]] – hKLK (mutant) + inhibitor <br /> | ||
| + | **[[5nx1]], [[5nx3]] – hKLK + amyloid-b A4 protein<br /> | ||
*Kallikrein 7 | *Kallikrein 7 | ||
| Line 59: | Line 61: | ||
**[[3bsq]] – hKLK <br /> | **[[3bsq]] – hKLK <br /> | ||
**[[2qxg]], [[2qxh]], [[2qxi]], [[2qxj]] – hKLK + chymotriptic determinant <br /> | **[[2qxg]], [[2qxh]], [[2qxi]], [[2qxj]] – hKLK + chymotriptic determinant <br /> | ||
| - | **[[5fah]] – hKLK + inhibitor<br /> | + | **[[5fah]], [[5y9l]], [[5yjk]] – hKLK + inhibitor<br /> |
| + | **[[5zfh]] – mKLK - mouse<br /> | ||
| + | **[[5zfi]] – mKLK + inhibitor<br /> | ||
| + | |||
| + | *Kallikrein 8 | ||
| + | |||
| + | **[[5ms3]] – hKLK <br /> | ||
| + | **[[5ms4]] – hKLK + inhibitor<br /> | ||
*Kallikrein 10 | *Kallikrein 10 | ||
| Line 76: | Line 85: | ||
**[[5f8t]] – hKLK light chain (mutant) + Pkalin-2 <br /> | **[[5f8t]] – hKLK light chain (mutant) + Pkalin-2 <br /> | ||
**[[5f8x]] – hKLK light chain (mutant) + Pkalin-3 <br /> | **[[5f8x]] – hKLK light chain (mutant) + Pkalin-3 <br /> | ||
| - | **[[5tjx]], [[2anw]], [[2any]] – hKLK light chain (mutant) + inhibitor <br /> | + | **[[5tjx]], [[2anw]], [[2any]], [[5tz9]] – hKLK light chain (mutant) + inhibitor <br /> |
| + | **[[5gvt]] – mKLK light chain (mutant) + <br /> | ||
*Tissue kallikrein (KLK 1) | *Tissue kallikrein (KLK 1) | ||
Revision as of 09:20, 24 July 2018
| |||||||||||
3D Structures of kallikrein
Updated on 24-July-2018
References
- ↑ Bryant JW, Shariat-Madar Z. Human plasma kallikrein-kinin system: physiological and biochemical parameters. Cardiovasc Hematol Agents Med Chem. 2009 Jul;7(3):234-50. PMID:19689262
- ↑ Feener EP. Plasma kallikrein and diabetic macular edema. Curr Diab Rep. 2010 Aug;10(4):270-5. doi: 10.1007/s11892-010-0127-1. PMID:20535647 doi:http://dx.doi.org/10.1007/s11892-010-0127-1
- ↑ Pampalakis G, Sotiropoulou G. Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer. Biol Chem. 2006 Jun;387(6):773-82. PMID:16800739 doi:http://dx.doi.org/10.1515/BC.2006.097
- ↑ Cerqueira C, Samperio Ventayol P, Vogeley C, Schelhaas M. Kallikrein-8 Proteolytically Processes Human Papillomaviruses in the Extracellular Space To Facilitate Entry into Host Cells. J Virol. 2015 Jul;89(14):7038-52. doi: 10.1128/JVI.00234-15. Epub 2015 Apr 29. PMID:25926655 doi:http://dx.doi.org/10.1128/JVI.00234-15
- ↑ Debela M, Magdolen V, Grimminger V, Sommerhoff C, Messerschmidt A, Huber R, Friedrich R, Bode W, Goettig P. Crystal structures of human tissue kallikrein 4: activity modulation by a specific zinc binding site. J Mol Biol. 2006 Oct 6;362(5):1094-107. Epub 2006 Aug 3. PMID:16950394 doi:10.1016/j.jmb.2006.08.003
